Clinical trial
Gemox as First and Second Line Therapy in Unknown Primary Cancer
NCT00353145 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00353145 |
|---|---|
| Title | Gemox as First and Second Line Therapy in Unknown Primary Cancer |
| Official title | A Phase II Study to Evaluate the Efficacy and Toxicity of Oxaliplatin in Combination With Gemcitabine as First and Second Line Therapy in Unknown Primary Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unknown Primary Neoplasms |
| Intervention type | Behavioral, Drug |
| Interventions | Gemcitabine (Gemox), Oxaliplatin, Questionnaire |
| Enrollment | 29 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Jul 17, 2006 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: